Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/9/2012

CRANBURY, N.J., Nov. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2012, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast

  • Q1 Fiscal Year 2013 Financial Results Press Release
  • 11/14/2012 at 7:30 a.m. ET

     

  • Q1 Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012 at 11:00 a.m. ET
    1-888-428-9490
    1-719-325-2354

    9649528

     

  • Q1 Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012-11/20/2012
    1-888-203-1112
    1-719-457-0820
    9649528

     

  • Webcast Live and Replay Access
  • http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.com. About Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
    3. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    4. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    5. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    6. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    7. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    10. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2017)... CA (PRWEB) , ... April 28, 2017 , ... ... announced the launch of a new neoadjuvant breast cancer monitoring (NEAT) study in partnership ... least 10 centers and over 150 patients to be monitored over two years with ...
    (Date:4/27/2017)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) today announced that its Board of ... of the company,s common stock. This program will became ... 2017. Purchases may be made in the open market, ... time to time as determined by United Therapeutics, management ...
    (Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Mitotech S.A, ... in Leber’s Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease ... of SkQ1 eye drops in a group of 20 patients carrying 11778, 14484 and ...
    (Date:4/27/2017)... ... April 27, 2017 , ... During ... will review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will ... and 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized ...
    Breaking Biology Technology:
    (Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
    (Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
    (Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
    Breaking Biology News(10 mins):